Chinese Companies Develop 87 Vaccines, 35 Anti-Tumor Drugs, 38 Gene Therapies, 150 Synthetic Meds
This article was originally published in PharmAsia News
Currently, drugs being developed by China’s 201 listed pharma companies spread across multiple categories with a total of 87 for vaccines, 35 for anti-tumor drugs, 38 for genetic engineering treatments, and 150 for synthetic medicines.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.